Payment overview · 2025
General Payments
$861.21
33 reported records · 16 companies
Healthcare provider profile · identity verified
Bruce A Bouts, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FINDLAY, OH · NPI 1164488268
Verified facts
What the public records show
CMS Open Payments records show Bruce A Bouts, M.D. received $861.21 in general payments during 2025 across 33 reported records.
Novo Nordisk Inc accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $196.43 | 22.8% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $133.89 | 15.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $117.92 | 13.7% | 8 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $103.15 | 12.0% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $52.93 | 6.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.78 | 5.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.00 | 4.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $28.40 | 3.3% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $27.04 | 3.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.68 | 2.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $22.50 | 2.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.00 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.54 | 1.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.16 | 1.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $14.03 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.76 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $861.21 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $117.92 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $117.92 | 8 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $103.15 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $95.00 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $95.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.43 | 5 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $52.93 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.78 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.89 | 2 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $28.40 | 1 | 2025 |
Source payment records
|
|||||
| EXOGEN ULTRASOUND BONE HEALING SYSTEM Normalized: exogen ultrasound bone healing system |
Device | Bioventus LLC | $27.04 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.02 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
111 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
115 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
312 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 846 | 222 |
| Amlodipine Besylate | Amlodipine Besylate | 747 | 185 |
| Omeprazole | Omeprazole | 569 | 145 |
| Lisinopril | Lisinopril | 533 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 510 | 126 |
| Losartan Potassium | Losartan Potassium | 474 | 133 |
| Hydrochlorothiazide | Hydrochlorothiazide | 466 | 124 |
| Metoprolol Tartrate | Metoprolol Tartrate | 446 | 107 |
| Metformin Hcl Er | Metformin Hcl | 348 | 89 |
| Eliquis | Apixaban | 312 | 56 |
| Simvastatin | Simvastatin | 307 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 283 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 271 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 79 |
| Gabapentin | Gabapentin | 237 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 210 | 58 |
| Tramadol Hcl | Tramadol Hcl | 206 | 42 |
| Bumetanide | Bumetanide | 202 | 56 |
| Ropinirole Hcl | Ropinirole Hcl | 197 | 34 |
| Metformin Hcl | Metformin Hcl | 195 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 187 | 48 |
| Alprazolam | Alprazolam | 184 | 49 |
| Meloxicam | Meloxicam | 179 | 44 |
| Furosemide | Furosemide | 172 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 165 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 165 | 41 |
| Lorazepam | Lorazepam | 165 | 47 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 136 | 40 |
| Allopurinol | Allopurinol | 135 | 37 |
| Warfarin Sodium | Warfarin Sodium | 131 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 23 |
| Donepezil Hcl | Donepezil Hcl | 119 | 27 |
| Carvedilol | Carvedilol | 118 | 29 |
| Glipizide | Glipizide | 117 | 26 |
| Jardiance | Empagliflozin | 115 | 21 |
| Potassium Chloride | Potassium Chloride | 114 | 35 |
| Cephalexin | Cephalexin | 112 | 82 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 112 | 32 |
| Prednisone | Prednisone | 112 | 46 |
| Synthroid | Levothyroxine Sodium | 111 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 105 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 22 |
| Sertraline Hcl | Sertraline Hcl | 102 | 29 |
| Glimepiride | Glimepiride | 99 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 36 |
| Telmisartan | Telmisartan | 99 | 21 |
| Chlorthalidone | Chlorthalidone | 96 | 24 |
| Januvia | Sitagliptin Phosphate | 93 | 17 |
| Clonazepam | Clonazepam | 85 | 24 |
| Atenolol | Atenolol | 83 | 18 |
| Ozempic | Semaglutide | 83 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 82 | 11 |
| Famotidine | Famotidine | 82 | 19 |
| Azithromycin | Azithromycin | 80 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 20 |
| Bupropion Xl | Bupropion Hcl | 74 | 11 |
| Sucralfate | Sucralfate | 74 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 16 |
| Glipizide Er | Glipizide | 71 | 18 |
| Trazodone Hcl | Trazodone Hcl | 67 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 15 |
| Montelukast Sodium | Montelukast Sodium | 63 | 22 |
| Clonidine Hcl | Clonidine Hcl | 62 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 12 |
| Spironolactone | Spironolactone | 58 | 17 |
| Celecoxib | Celecoxib | 57 | 12 |
| Pregabalin | Pregabalin | 57 | 13 |
| Baclofen | Baclofen | 55 | 14 |
| Nifedipine Er | Nifedipine | 55 | 13 |
| Buspirone Hcl | Buspirone Hcl | 54 | suppressed |
| Ramipril | Ramipril | 54 | 16 |
| Valacyclovir | Valacyclovir Hcl | 52 | 19 |
| Mirtazapine | Mirtazapine | 51 | 15 |
| Mupirocin | Mupirocin | 50 | 31 |
| Cefuroxime | Cefuroxime Axetil | 49 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 19 |
| Ezetimibe | Ezetimibe | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 12 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 13 |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Naproxen | Naproxen | 46 | 11 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 46 | 11 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Nabumetone | Nabumetone | 43 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | 14 |
| Nystatin | Nystatin | 40 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Verapamil Er | Verapamil Hcl | 38 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Lovastatin | Lovastatin | 36 | 11 |
| Clotrimazole | Clotrimazole | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 24 |
| Rasagiline Mesylate | Rasagiline Mesylate | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Loperamide | Loperamide Hcl | 32 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 21 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Valproic Acid | Valproic Acid | 31 | 11 |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 18 |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Trimethoprim | Trimethoprim | 26 | 21 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 24 |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 12 |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 17 |
| Valsartan | Valsartan | 24 | suppressed |
| Haloperidol | Haloperidol | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Jantoven | Warfarin Sodium | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Terconazole | Terconazole | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $861.21 · 33 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, Bimzelx, CUTAQUIG, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, EXOGEN ULTRASOUND BONE HEALING SYSTEM, FREESTYLE LIBRE 3, JOURNAVX, MOUNJARO, NEFFY, OCTAGAM IMMUNE GLOBULIN (HUMAN), OTEZLA, Ohtuvayre, Ozempic, PANZYGA, REPATHA, Rybelsus, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error